World-first adaptive dosing trial improves prostate cancer survival

Recent advancements in prostate cancer treatment are showing promising results, particularly through a world-first medical trial in Australia utilizing adaptive dosing to improve survival rates and reduce side effects compared to traditional chemotherapy. This innovative approach involves regular scans to guide radiation dosage, significantly enhancing patients' quality of life. Concurrently, a mid-stage study presented at the 2025 ASCO Genitourinary Cancers Symposium indicates that transdermal estradiol patches can effectively deliver androgen deprivation therapy with fewer side effects than traditional methods. These patches not only suppress testosterone but also improve bone density and reduce hot flashes, although they may lead to breast tissue enlargement in some patients. Experts emphasize the importance of early diagnosis and treatment, as many men are hesitant to discuss prostate health. Together, these developments represent significant strides in managing prostate cancer and improving patient outcomes.